Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy—An Italian multicenter experience.

e12087Background: Chemotherapy (CT) plus targeted therapy is the established treatment for HER2 overexpressing breast cancer (BC) patients (pts). The debate about anti-HER2 combination beyond standard therapies is still unresolved. Limited data regarding the safety and activity of the combination of eribulin and trastuzumab (E/T) in pretreated HER2-positive advanced breast cancer (ABC) are available. The aim of this observational, retrospective, multicenter study was to examine the tolerability and the clinical activity of eribulin plus trastuzumab in this setting. Methods: Pts treated with eribulin mesylate (1.23 mg/m2 administered via intravenous infusion on Days 1 and 8 each 21-day cycle) plus standard dose of trastuzumab (16 pts received 3-week schedule: 8 mg/kg load, 6 mg/kg q 3 weeks; 3 pts received weekly schedule: 4 mg/kg load, 2 mg/kg q week) were included. Data on overall response rate (ORR), progression free survival (PFS), post-progression survival (PPS), overall survival (OS) and safety were ...